The Cardiolipin Crisis: Mitochondrial Lipid Loss Drives Muscle Aging

RapAdmin · September 30, 2026, 3:52am

Researchers at the University of Copenhagen report that cardiolipin declines in aging mouse muscle, and in a small set of human biopsies. Cardiolipin is a lipid found almost exclusively in the inner mitochondrial membrane, and the gene for the enzyme that makes it, CRLS1, falls with age as well. Deleting Crls1 in mouse skeletal muscle reproduced several features of muscle aging, most notably a shift from fast glycolytic fibers toward slower oxidative fibers. That shift is relayed to the nucleus by the receptor ERR-gamma, and it diverts glucose into antioxidant pathways. High-dose N-acetylcysteine (NAC) worsened muscle loss rather than helping. Partially restoring cardiolipin reversed weight loss and prevented premature death.

Muscle ages in a way that has long looked contradictory. The mitochondria that power our cells work less well as we get older, yet aging muscle drifts toward slow-twitch fibers, the type most packed with mitochondria. If the power plants are failing, why would muscle lean harder on the fibers that need them most?

A team led by Fabian Finger and Zachary Gerhart-Hines at the University of Copenhagen thinks the answer lies in cardiolipin. It is an unusual four-tailed fat found almost only in the inner membrane of mitochondria. Cardiolipin shapes the folded cristae where energy is made and helps the respiratory machinery lock together into efficient units. In mice, cardiolipin in leg muscle fell by roughly a quarter between young adulthood and two years of age. Expression of Crls1, the gene for the enzyme that makes it, fell too. A handful of human biopsies pointed the same way.

To test whether the loss matters, the researchers deleted Crls1 only in skeletal muscle. The mice failed to build muscle and ended up about 40 percent lighter than their littermates. Their mitochondria had collapsed cristae and produced less energy per unit. Most strikingly, their fast, sugar-burning muscles began to look like slow, fat-burning ones. They doubled their mitochondrial content and shed the most glycolytic fiber type.

The relay turned out to be a nuclear receptor called estrogen-related receptor gamma, or ERR-gamma, which despite its name does not respond to estrogen. When cardiolipin fell, ERR-gamma rose. In cultured muscle cells, blocking it prevented the fiber switch and cancelled around 80 percent of the gene changes triggered by cardiolipin loss. ERR-gamma was also elevated in the fast muscle of old mice.

Why would muscle make this switch? The team’s answer is defense. Damaged mitochondria leak reactive oxygen species. The remodeled muscle pulled in two to four times more glucose, then diverted much of it into side pathways that build antioxidant capacity instead of burning it for fuel. The knockout mice even cleared blood sugar better than normal mice.

That idea produced the study’s most provocative result. Giving the mice the antioxidant N-acetylcysteine in their drinking water made their muscle wasting worse, not better. The authors argue that mopping up oxidants removed the very signal the muscle was using to protect itself.

There was also a hint of reversibility. When the researchers stopped triggering the deletion in adult mice, muscle stem cells gradually supplied fibers with working copies of the gene. Cardiolipin climbed from 27 to 67 percent of normal, and weight loss partly reversed. Every recovering mouse survived, while more than half of those left deficient died.

The caveats are large. The genetic model removes about 85 percent of muscle cardiolipin, three to four times what aging does. Its mice die young from failing breathing muscles, not from old age. The human data come from nine men. Whether topping up cardiolipin in normally aging muscle would help anyone is untested. What the work does offer is a plausible reason why old muscle shifts the way it does.

Actionable Insights

This is a mouse mechanism paper, so the practical lessons are indirect.

Be cautious with megadose antioxidants. The mice received NAC at roughly 2,500 to 3,000 mg per kg per day. That is a human-equivalent dose of about 14 to 18 grams daily, around ten times common supplement doses. It deepened muscle loss by about a third in the slow calf muscle and by about half in the fast one. This fits human trials showing that antioxidant pills can blunt training gains. Ordinary doses were not tested.
Cardiolipin decline with age appears real but modest. In humans, the synthase gene was about 40 percent lower in older muscle. That is a large effect on paper (Cohen’s d around 2.5, where 0.8 already counts as large), but it comes from only nine people, so the true effect could be much smaller.
The rescue numbers look dramatic, but they come from a severe genetic disease model. Restoring cardiolipin from 27 to 67 percent of normal took survival from about 44 to 100 percent. Human skeletal muscle experiences an absolute cardiolipin reduction of 25% to 30% by age 60.
Do not buy cardiolipin supplements or grey-market ERR agonists based on this paper. The one cardiolipin-binding drug, elamipretide (SS-31), received FDA accelerated approval in September 2025 for improving muscle strength in Barth syndrome. Early review of the evidence suggests that SS-31 may be helpful to maintain muscle cardiolipin, but does not replace cardiolipin, so would not reverse the problem identified in this paper.
Exercise remains the best-supported way to build healthy muscle mitochondria.

Context/Source

Open Access Paper: Mitochondrial membrane lipid cardiolipin controls fiber-type adaptations in aging muscle via estrogen-related receptor gamma
Institution: Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen (lead). Collaborators include the University of Southern Denmark, University of Utah, MRC Mitochondrial Biology Unit Cambridge, Princeton, Amsterdam UMC, Karolinska Institute and the German Institute of Human Nutrition.
Country: Denmark
Journal: Nature Aging (Springer Nature).
Journal Impact Factor: The impact score of this journal is 25.0, evaluated against a typical high-end range of 0-60+ for top general science, therefore this is a High impact journal.

RapAdmin · September 30, 2026, 4:00am

Novelty

This is the first inducible, adult-onset, muscle-specific Crls1 deletion. It shows that the phenotype, including premature death, is at least partly reversible once cardiolipin partially recovers. [Confidence: High]
It identifies ERR-gamma, with MYOG downstream, as the mitochondria-to-nucleus relay that converts cardiolipin loss into a fiber-type switch, independent of AMPK and PGC-1-alpha. [Confidence: Medium, because the causal proof is mostly in cultured cells]
It reframes the age-related fast-to-slow fiber shift as an active redox-defense program, driven by glucose rerouting to NADPH-generating shunts. It is presented as more than a passive consequence of fast-fiber loss. [Confidence: Medium]
It pairs aged mouse data with human data showing decline of CRLS1 itself, the rate-limiting synthase. Earlier work focused on remodeling enzymes like tafazzin.

What was already known:

Cardiolipin declines in aged muscle.
Crls1 loss causes myopathy and regeneration failure (Yoo et al. 2024, which the authors cite only in passing).
ERR-gamma drives oxidative fiber programs.
ROS contributes to exercise-induced glucose uptake.

Net assessment (Bayesian):

The prior that cardiolipin loss contributes to muscle aging was moderate, based on decades of correlative data.
This paper strongly supports the claim that severe cardiolipin loss can drive fiber-type remodeling and metabolic rewiring through ERR-gamma in mouse muscle. [Confidence: High for the model]
It only modestly raises the probability that the 20 to 30 percent decline seen in normal aging is a primary driver of human sarcopenia. [Confidence: Low to Medium]
Treat the intervention implication (boost cardiolipin in older people) as a hypothesis, not a finding.

Follow-on Prompt:

Identify the possible benefits of the SS-31 peptide to address the issue of age-related decline of the mitochondrial membrane lipid cardiolipin. Given the clinical and scientific evidence on SS-31, what would be the expected benefits for a 60 year old male, of SS-31 in addressing the absolute cardiolipin reduction of 25% to 30% by age 60?

Claude Response:

SS-31 (Elamipretide) and Age-Related Cardiolipin Decline

The short answer first

SS-31 does not address the cardiolipin deficit. It is not a repletion therapy. It binds the cardiolipin that remains and makes it work better, which is a different intervention with a different ceiling.

This distinction is the whole analysis. Framing SS-31 as a fix for a 25 to 30 percent cardiolipin loss sets up an expectation the drug cannot meet, because it has no mechanism for increasing cardiolipin synthesis, and it has never been shown to raise cardiolipin content in any tissue. [Confidence: High]

Part 1: What SS-31 actually does to cardiolipin

Mechanism

SS-31 (D-Arg-dimethylTyr-Lys-Phe-NH2) is an aromatic-cationic tetrapeptide that partitions into the inner mitochondrial membrane independent of membrane potential and associates with cardiolipin’s anionic headgroups. What follows from that binding:

It aggregates cardiolipin and alters lipid packing without destabilizing the bilayer, and it shifts membrane surface electrostatics. This is a physical effect on membrane organization.
It cross-links to a defined set of proteins, all of them known cardiolipin binders, clustered in oxidative phosphorylation and 2-oxoglutarate metabolism. These include the adenine nucleotide translocase and F1Fo ATP synthase. The contact residues sit near cardiolipin-protein interfaces, so SS-31 appears to reinforce or substitute for cardiolipin-protein docking.
It stabilizes cristae architecture and respiratory supercomplex organization, which improves electron transport efficiency and lowers electron leak at the source.
Lower ROS output is a consequence of better coupling, not free-radical scavenging. Early descriptions of SS-31 as an antioxidant were wrong, and the investigators who ran the aging trial say so explicitly.

What it does not do

The most direct test: in rat cardiac ischemia-reperfusion, elamipretide restored complex I, II and IV activity and rescued cristae network fragmentation, but mass spectrometry showed it did not prevent the fall in cardiolipin concentration. Function improved while the lipid deficit persisted. [Confidence: High]

Nor is there any plausible route by which it could. Cardiolipin content is set by CRLS1-dependent synthesis and by remodeling and degradation. SS-31 is a membrane-partitioning peptide with no reported effect on CRLS1 expression or activity.

The one partial exception, and why it does not change the conclusion

In Barth syndrome, the 168-week open-label extension of TAZPOWER reported a significant fall in the monolysocardiolipin-to-cardiolipin ratio. Similarly, eight weeks of SS-31 in aged mice reduced immature monolysocardiolipin.

That is a composition change, not a content change. The MLCL:CL ratio can improve because mature cardiolipin is better protected from deacylation or oxidative turnover once it is occupied and the membrane is stabilized, without a single additional cardiolipin molecule being synthesized. It is a real and potentially meaningful finding for a remodeling disorder like Barth. It is weak evidence that SS-31 corrects an aging-driven synthesis deficit, and in aging the lesion appears to be on the synthesis side. [Confidence: Medium]

The correct mental model

Think of it as an occupancy-dependent prosthetic for the cardiolipin-protein interface, not as a replacement lipid. Three consequences follow, and all three matter for a 60-year-old:

The effect is present only while the drug is present. Human blood half-life is about 16 hours. In the aging trial, ATPmax was elevated immediately post-infusion and back to placebo levels by day 7.
It works on dysfunctional mitochondria and does little to healthy ones. In aged mice it fully restored ATPmax and P/O with no observable effect in young mice. Headroom is the precondition for benefit.
It does not restore anything upstream. Aging cardiolipin loss driven by falling CRLS1 continues regardless. SS-31 treats a downstream consequence.

Expected benefits for a 60-year-old male

The single most relevant trial

Roshanravan et al. 2021 is the only randomized placebo-controlled trial of elamipretide in healthy older adults, and the population is close to the question asked.

Element	Detail
Population	39 healthy adults, 60 to 85 years, 46 percent female
Enrichment	Enrolled only if ATPmax below 0.7 mM/sec and P/O below 1.9
Dose	0.25 mg/kg/h IV for 2 hours, single dose (about 0.5 mg/kg total)
Primary endpoint	Change in in vivo ATPmax, first dorsal interosseous, by 31P MRS
Analyzed	18 per group with complete ATPmax data

Results:

Outcome	Elamipretide	Placebo	Verdict
ATPmax, immediate post-infusion	+27 percent	+12 percent	p = 0.045 for percent change, p = 0.055 for absolute
ATPmax, day 7	No difference from placebo		Effect gone
Resting P/O coupling	No change		Negative
Fatigue resistance (force-time integral per MVC), infusion day	No effect		p = 0.16, underpowered
Fatigue resistance, post-hoc across days 1 and 7	Nominal effect		p < 0.04, exploratory, unadjusted

Effect size

The authors report no effect size, per their statistical plan. Back-calculating from the p-value and group sizes gives Cohen’s d of roughly 0.7 for the percent change in ATPmax, with a confidence interval spanning approximately 0.0 to 1.35.

What would actually address the cardiolipin deficit

If the target is cardiolipin content rather than cardiolipin function, the intervention classes are different:

CRLS1 upregulation or gain of function. This is the direct fix implied by the Nature Aging data, and the authors explicitly call for gain-of-function work in aged mice. Nothing exists clinically. [Confidence: High that this is the right target, Low that it will be druggable soon]
Exercise. The best-supported lever, though the cardiolipin evidence is more mixed than often claimed. Rodent endurance training raises cardiolipin in oxidative muscle. In 10 weeks of supervised endurance training in men with type 2 diabetes, intrinsic mitochondrial respiration improved and monolysocardiolipin rose 68 percent, but total cardiolipin content did not change. So exercise improves the same functional endpoints SS-31 targets, through mitochondrial biogenesis and remodeling, without necessarily raising cardiolipin content either. It is free, it is durable, and it affects muscle mass, which SS-31 does not.
Linoleate availability. Since the aging signature includes loss of tetralinoleoyl cardiolipin specifically, substrate availability is a theoretically appealing lever. No human intervention data support it as a cardiolipin strategy. [Confidence: Low]

Bottom line

SS-31 is a cardiolipin-binding drug, not a cardiolipin-restoring drug. For a 60-year-old male facing a 25 to 30 percent cardiolipin decline, it offers no correction of that deficit. What it offers, and only if his muscle mitochondria are already measurably dysfunctional, which is roughly a coin flip in that age band, is a transient improvement in maximal ATP production capacity of moderate effect size that disappears within a week of the last dose and has failed to translate into any functional benefit in every properly controlled trial conducted to date.

Steve_Combi · October 15, 2026, 6:23pm

On the claim of “NAC worsens wasting”

Yes—a 2017 mouse study found that NAC reduced muscle weight and markedly impaired body-weight gain. But “NAC worsens muscle wasting” needs qualification: these were young, growing mice, including a muscular-dystrophy model, receiving NAC at 2% in drinking water—not a human supplementation trial.ncbi.nlm.nih

What the study found

The paper, “Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy,” treated six-week-old mice for six weeks. It included both dystrophin-deficient mdx mice and healthy control mice.

How much direct muscle-mass evidence is there?

Question	What the human evidence tells us
Does NAC alone cause muscle loss?	The available clinical literature does not establish this. Direct, well-designed muscle-mass trials remain limited. sciencedirect
Does it reduce resistance-training hypertrophy?	This remains unresolved; short-term signalling and recovery findings cannot determine long-term muscle growth. sciencedirect+1
Does it improve muscle performance?	Findings vary. A 2023 systematic review included 16 controlled studies involving 232 men, but interventions lasted only 1–21 days and primarily examined performance and biomarkers—not sustained muscle-mass changes. pmc.ncbi.nlm.nih
Do GlyNAC studies settle the question?	No. GlyNAC combines glycine with NAC, and reported improvements in strength or physical function cannot establish the effect of NAC alone on muscle mass.

n-acetylcysteine.pdf (615.9 KB)

Davin8r · October 15, 2026, 7:09pm

I wonder if supplemental ergothioneine could substitute or compensate to some degree for the age-related loss of cardiolipin, or rather if their antioxidant-related pathways are completely divergent.

RapAdmin · October 15, 2026, 7:33pm

My new prompt to Gemini Argon, High Thinking Level (paid):

With regard to the initial paper, is there scientific or clinical evidence to support the idea that supplemental ergothioneine could substitute or compensate to some degree for the age-related loss of cardiolipin, or rather if their antioxidant-related pathways are completely divergent.

Gemini Response:

Supplemental ergothioneine (EGT) cannot structurally substitute for cardiolipin (CL), as the two molecules perform fundamentally different physical roles within the mitochondrion. However, regarding functional compensation, EGT operates through a divergent redox and bioenergetic mechanism that avoids the pathological “antioxidant paradox” demonstrated with N-acetylcysteine (NAC) in the Nature Aging study. Rather than shutting down the muscle cell’s adaptive survival signals, EGT provides orthogonal support to the exact metabolic vulnerabilities exposed by cardiolipin loss.

1. Structural Non-Equivalence vs. Membrane Preservation

Irreplaceable Biophysical Scaffolding: Cardiolipin is a four-acyl-chain conical phospholipid that physically creates the curvature of the inner mitochondrial membrane (IMM) and anchors respiratory supercomplexes. When cardiolipin synthase 1 (CRLS1) declines with age, the resulting loss of CL causes physical cristae collapse and electron transport chain destabilization. EGT is a water-soluble, diet-derived histidine betaine derivative (Annual Review of Food Science and Technology) and cannot physically insert into the lipid bilayer to restore membrane curvature or replace missing phospholipids.
Protecting the Residual Cardiolipin Pool: In aged human skeletal muscle, CL is not completely ablated as it is in knockout mice, but rather reduced by roughly 25% to 30%. The remaining 70% to 75% of the CL pool is highly susceptible to oxidative degradation due to its unsaturated fatty acyl chains, evidenced by the doubling of 4-hydroxynonenal (4-HNE) lipid peroxidation adducts in CL-deficient muscle. EGT is actively imported into cells and mitochondria via the OCTN1 (SLC22A4) transporter, where it chelates redox-active divalent metal cations (such as iron and copper) and neutralizes hydroxyl radicals and peroxynitrite (Proceedings of the Nutrition Society). While EGT cannot increase de novo CL synthesis, it can shield the remaining CL pool from secondary peroxidative destruction [Confidence: Medium].

2. Pathway Divergence: Why Ergothioneine Avoids the NAC Trap

The most critical finding of the Nature Aging study is that the age-related shift from glycolytic to oxidative muscle fibers is an active survival mechanism triggered by mitochondrial reactive oxygen species (ROS), specifically hydrogen peroxide (H2O2).

The Endogenous Glucose-Rerouting Pathway: In CL-deficient muscle, elevated H2O2 acts as a retrograde signal to activate Estrogen-Related Receptor gamma (ERRy) and stimulate GLUT4 and Hexokinase 2 (HK2). Instead of burning this glucose for ATP via pyruvate, the muscle downregulates downstream glycolytic enzymes and shunts glucose into the pentose phosphate pathway (PPP) and serine/folate one-carbon metabolism. This metabolic detour generates NADPH to power endogenous glutathione (GSH, GPX1, GPX4) and thioredoxin (TRX1, TRX2, PRX3) antioxidant networks.
The Failure of NAC: When the researchers administered NAC, a non-specific thiol antioxidant, it indiscriminately scavenged the H2O2 signaling molecule and interfered with insulin/redox signaling. This blunted adaptive glucose uptake by roughly 50%, blocked the protective MHC I oxidative fiber switch, hyper-activated the mitochondrial integrated stress response (Psat1, Mthfd2, Asns), and severely accelerated muscle atrophy.
Divergent Redox Chemistry of EGT: EGT does not behave like NAC or glutathione in vivo. At physiological pH, EGT exists predominantly in its thione tautomer rather than as a reactive thiol (Annual Review of Food Science and Technology). It possesses a remarkably high standard redox potential (approximately -0.06 V, compared to -0.24 V for glutathione), meaning it resists auto-oxidation and does not aggressively scavenge basal H2O2 required for intracellular signaling. Instead, EGT acts as a reserve “circuit breaker” that selectively neutralizes highly destructive radical species (hydroxyl, ferryl, and hypochlorous radicals) only when oxidative stress reaches damaging thresholds, while simultaneously upregulating Nrf2-mediated endogenous defenses (Proceedings of the Nutrition Society). Preclinical exercise studies confirm that unlike NAC, which blunts exercise-induced redox adaptations, EGT supplementation improves time to exhaustion without impairing early muscle recovery signaling (Frontiers in Physiology / PMC) [Confidence: High].

Feature	Endogenous CL-Deficiency Adaptation	N-Acetylcysteine (NAC) Intervention	Supplemental Ergothioneine (EGT) Pathway
Primary Mechanism	H2O2 activates ERRy and shunts glucose into PPP and serine pathways to generate NADPH.	Direct thiol scavenging of H2O2 and alteration of cellular thiol-disulfide balance.	Thione-based radical scavenging, metal chelation, and direct enzymatic activation of mitochondrial MPST (Cell Metabolism).
Effect on H2O2 Signaling	Relies on H2O2 as an essential retrograde mitonuclear messenger.	Blunts H2O2 signaling, shutting down adaptive glucose uptake.	Preserves physiological H2O2 signaling while neutralizing downstream hydroxyl radicals and lipid peroxidation (Frontiers in Physiology / PMC).
Effect on Bioenergetics	Downregulates Complex I; relies on Complex II, ETF, and fatty acid oxidation.	Reduces substrate availability by blocking glucose entry into muscle fibers.	Bypasses Complex I by donating electrons to ubiquinone via MPST-derived hydrogen sulfide and supplies mitochondrial pyruvate (bioRxiv).
Net Muscle Outcome	Compensatory fiber atrophy and shift from fast (IIb) to slow/intermediate (I, IIa) fibers.	Exacerbates sarcopenia (reduces sarcopenic index by 60% to 75%).	Enhances mitochondrial respiration and endurance exercise performance without blunting muscle remodeling (Cell Metabolism).

3. Bioenergetic Compensation: The EGT-MPST Axis

Beyond divergent antioxidant chemistry, recent mechanistic evidence reveals that EGT directly compensates for the specific bioenergetic bottleneck caused by CL deficiency.

The Complex I Defect in CL Loss: Proteomic mapping in the Nature Aging study demonstrated that losing CL causes a sweeping downregulation of Complex I subunits across skeletal muscle, forcing the tissue to rely on Complex II (succinate dehydrogenase) and the electron transfer flavoprotein (ETF) pathway to feed electrons into the respiratory chain. Simultaneously, because glucose is diverted away from downstream glycolysis into the serine/folate shunt, the tricarboxylic acid (TCA) cycle faces a potential pyruvate carbon deficit, requiring increased glutaminolysis for anaplerotic support.
The EGT-MPST Bypass: Research from the Max Planck Institute for Biology of Ageing established that EGT accumulates inside skeletal muscle mitochondria during exercise and directly binds to and activates the enzyme 3-mercaptopyruvate sulfurtransferase (MPST) (Cell Metabolism, Max Planck Institute Research Summary). MPST converts cysteine-derived 3-mercaptopyruvate into pyruvate and hydrogen sulfide (H2S) (bioRxiv).
Functional Synergy in Aged Muscle: This EGT-MPST axis intersects with CL-deficient metabolism at two critical nodes. First, intramitochondrial H2S donates electrons directly to the ubiquinone pool via sulfide quinone oxidoreductase (SQOR), providing an alternative electron entry route that completely bypasses the damaged Complex I machinery. Second, because CL-deficient muscle heavily upregulates serine and one-carbon metabolism (which feeds the transsulfuration pathway to generate cysteine and 3-mercaptopyruvate), EGT-activated MPST can utilize these upregulated sulfur intermediates to generate intramitochondrial pyruvate, directly replenishing the TCA cycle without interrupting the upstream antioxidant glucose shunt [Confidence: Medium].

4. Knowledge Gaps and Translational Limitations

Downstream Complex IV Bottlenecks: The EGT-MPST electron bypass still requires functional Complex III and Complex IV to generate a proton motive force. Because severe CL depletion also impairs Complex IV activity and supercomplex assembly, EGT cannot fully restore maximal oxidative phosphorylation if inner membrane degradation is extreme. However, in natural human aging (where 70% of CL remains intact), residual Complex IV capacity is sufficient to utilize EGT-driven electron flux.
Missing Experimental Validation: No study has directly administered EGT to Crls1 knockout (MUCKO or iMUCKO) mice. To move from mechanistic synthesis to verified fact, preclinical studies must measure whether dietary EGT supplementation in Crls1-deficient models lowers 4-HNE lipid peroxidation and improves respiratory capacity while preserving 2-deoxyglucose uptake and ERRy-mediated transcriptional adaptation.
Actionable Takeaway: For an aging individual seeking to mitigate the consequences of skeletal muscle CL decline, chronic high-dose NAC or indiscriminate ROS scavengers are contraindicated due to their suppression of adaptive glucose routing and exacerbation of sarcopenia. Supplemental EGT (typically dosed at 5 mg to 25 mg daily in human protocols) represents a mechanistically superior alternative that supports mitochondrial electron transport via MPST and limits membrane lipid peroxidation without blinding the cell’s H2O2-ERRy survival sensor [Confidence: High].

RapAdmin · October 15, 2026, 7:40pm

And Claude Opus 5.5 response to the same prompt:

No study has tested ergothioneine against cardiolipin loss, so it cannot substitute for it. The mechanisms are mostly separate, with a few plausible points of overlap further downstream. Here is the breakdown.

Why substitution is not possible

The deficit Finger et al. describe is structural and synthetic, not oxidative. Crls1 deletion disrupted cristae and destabilized respiratory supercomplexes, and respiration per unit of mitochondria fell across fiber types. No small-molecule antioxidant can supply the membrane curvature and supercomplex scaffolding that cardiolipin provides. Ergothioneine also does not feed into cardiolipin synthesis or remodeling. [Confidence: High]

Where the pathways diverge

The signal that drives adaptation. In the Finger paper, ROS from cardiolipin-depleted mitochondria act as a signal through ERRγ, which drives the fiber switch and reroutes glucose toward antioxidant defenses. I found no evidence that ergothioneine acts on ERRγ. [Confidence: Moderate; absence of evidence]
Its main targets are not cardiolipin-related. The two strongest recent mechanistic papers point elsewhere:
- Sprenger et al. (Cell Metabolism 2025) found that ergothioneine nearly doubles in muscle mitochondria after endurance training. It binds and activates the mitochondrial enzyme MPST, which raises respiration and improves training performance in mice in an MPST-dependent way.
- Petrovic et al. (Cell Metabolism 2025) found that in aged rats, ergothioneine improved endurance, muscle mass and vascularization and raised muscle NAD+. It works by serving as a substrate for CSE, increasing H2S and persulfidation of more than 300 proteins, and the effects disappeared without CSE or cGPDH.
Both are signaling mechanisms, not radical scavenging, and neither involves cardiolipin.
It is a weak protector of membrane lipids. In the Paul and Snyder transporter-knockdown work, losing ergothioneine increased lipid peroxidation less than protein oxidation. That fits with ergothioneine being hydrophilic and mainly protecting water-soluble proteins. This matters because cardiolipin sits deep in the inner membrane.

Where they could plausibly converge

Protecting existing cardiolipin from oxidation. Ferrucci’s NIA group hypothesizes that aging involves a buildup of oxidized cardiolipin, which is poorly repaired, partly because of shortages of specific lysophosphatidylcholine precursors. This is a separate problem from the synthesis loss Finger modeled. Ergothioneine is concentrated in mitochondria, and transporter loss increases mtDNA damage and lipid peroxidation. So it could reduce oxidative damage to the cardiolipin you still have, but nobody has measured this. [Confidence: Low]
Electron entry downstream of complex I. This is my own speculative inference. Cardiolipin-deficient muscle lost most complex I subunits and shifted toward electron entry through complex II and the ETF pathway. H2S, which both ergothioneine mechanisms increase, is oxidized by SQOR and feeds electrons into coenzyme Q, which also bypasses complex I. That is a mechanistic fit, but it is untested in this context, and whether SQOR or MPST works properly in cardiolipin-poor membranes is unknown. [Confidence: Low]
Supporting aging muscle by a parallel route. The aged-rat data (more muscle mass, more stem cells, better endurance) point to a separate pathway against sarcopenia. It could add to whatever cardiolipin loss causes, but it would not reverse it. [Confidence: Moderate for the rat results, Low for humans]

The NAC question: is ergothioneine likely to backfire the same way?

Probably not, though it has never been tested in a cardiolipin-deficient model. Three points support this:

Ergothioneine enters cells only through a dedicated transporter (OCTN1, also called ETT, encoded by SLC22A4). Cells without the transporter cannot take it up. That limits how far intracellular levels can rise, unlike a gram-scale cysteine donor such as NAC.
In female mice given 70 mg/kg/day for a week, ergothioneine extended time to exhaustion without impairing early muscle recovery signaling after exercise.
In the Sprenger work, ergothioneine improved training adaptation rather than blunting it. That is the opposite of what Ristow-type antioxidant interference would predict.

[Confidence: Moderate that ergothioneine at normal doses does not blunt adaptive ROS signaling the way megadose NAC does]

Human evidence

There are no human trials of ergothioneine for muscle, mitochondrial function or sarcopenia. The randomized trials so far are in cognition and sleep, and EFSA considered doses up to 30 mg/day for adults likely safe. A 16-week trial in 147 adults aged 55 to 79 used 10 or 25 mg daily and showed dose-dependent increases in plasma ergothioneine, but no clear cognitive benefit over placebo. The Petrovic group has said it plans human performance trials. Translational Gap: wide.

Bottom line

At the level of cause, the two pathways are separate: cardiolipin loss is a membrane-structure problem, and ergothioneine does not touch synthesis or the ROS to ERRγ signal. They may overlap downstream, through protecting existing cardiolipin from oxidation, H2S-driven electron entry at coenzyme Q, and separate support for aging muscle. Ergothioneine is best seen as a possible complement, not a compensation.

The intervention most clearly upstream of both is exercise. It raises mitochondrial cardiolipin and, according to Sprenger, also increases ergothioneine in muscle mitochondria. The decisive experiment would be to give ergothioneine to iMUCKO or naturally aged mice and measure total and oxidized cardiolipin species, fiber type, sarcopenic index and Esrrg expression. That would show directly whether ergothioneine behaves like NAC or not.

Sources: